CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs
Bausch Health Canada (NYSE:BHC) announced that its acne treatment CABTREO is now available through public drug plans in Ontario and Nova Scotia, as well as two federal programs - the Non-Insured Health Benefits (NIHB) for Indigenous populations and the Correctional Service of Canada (CSC).
CABTREO is a first-of-its-kind triple-combination topical prescription treatment for acne vulgaris, approved by Health Canada for patients 12 years and older. The treatment combines three mechanisms of action: an antibiotic (clindamycin phosphate), a retinoid (adapalene), and an antibacterial agent (benzoyl peroxide). The once-daily gel is currently available through most private insurance plans, with plans to expand access through other public drug plans across Canada.
Bausch Health Canada (NYSE:BHC) ha annunciato che il suo trattamento per l'acne CABTREO è ora disponibile attraverso i piani pubblici di assistenza farmaceutica in Ontario e Nuova Scozia, oltre a due programmi federali: il Non-Insured Health Benefits (NIHB) per le popolazioni indigene e il Correctional Service of Canada (CSC).
CABTREO è un trattamento topico prescrivibile di nuova generazione con tripla combinazione per l'acne volgare, approvato da Health Canada per pazienti di età pari o superiore a 12 anni. Il trattamento combina tre meccanismi d'azione: un antibiotico (clindamicina fosfato), un retinoide (adapalene) e un agente antibatterico (perossido di benzoile). Il gel da applicare una volta al giorno è attualmente disponibile tramite la maggior parte delle assicurazioni private, con l'intenzione di estendere l'accesso ad altri piani pubblici in tutto il Canada.
Bausch Health Canada (NYSE:BHC) anunció que su tratamiento para el acné CABTREO ya está disponible a través de los planes públicos de medicamentos en Ontario y Nueva Escocia, así como en dos programas federales: el Non-Insured Health Benefits (NIHB) para poblaciones indígenas y el Correctional Service of Canada (CSC).
CABTREO es un tratamiento tópico de prescripción con triple combinación único en su tipo para el acné vulgar, aprobado por Health Canada para pacientes de 12 años en adelante. El tratamiento combina tres mecanismos de acción: un antibiótico (clindamicina fosfato), un retinoide (adapaleno) y un agente antibacteriano (peróxido de benzoilo). El gel de aplicación diaria está actualmente disponible a través de la mayoría de los planes de seguro privados, con planes para ampliar el acceso mediante otros planes públicos de medicamentos en todo Canadá.
Bausch Health Canada (NYSE:BHC)는 여드름 치료제 CABTREO가 온타리오와 노바스코샤의 공공 의약품 보험 프로그램뿐만 아니라 원주민을 위한 비보험 건강 혜택(NIHB)과 캐나다 교정 서비스(CSC)라는 두 연방 프로그램을 통해 제공된다고 발표했습니다.
CABTREO는 12세 이상 환자를 대상으로 Health Canada에서 승인한 세계 최초의 3중 복합 국소 처방 치료제입니다. 이 치료제는 항생제(클린다마이신 인산염), 레티노이드(아다팔렌), 항균제(과산화벤조일) 세 가지 작용 기전을 결합한 제품입니다. 하루 한 번 바르는 젤 형태로 현재 대부분의 민간 보험에서 이용 가능하며, 캐나다 전역의 다른 공공 의약품 보험으로 접근성을 확대할 계획입니다.
Bausch Health Canada (NYSE:BHC) a annoncé que son traitement contre l'acné CABTREO est désormais disponible via les régimes publics de médicaments en Ontario et en Nouvelle-Écosse, ainsi que par deux programmes fédéraux : les Non-Insured Health Benefits (NIHB) pour les populations autochtones et le Correctional Service of Canada (CSC).
CABTREO est un traitement topique sur ordonnance unique en son genre combinant trois agents contre l'acné vulgaire, approuvé par Santé Canada pour les patients de 12 ans et plus. Ce traitement associe trois mécanismes d'action : un antibiotique (phosphate de clindamycine), un rétinoïde (adapalène) et un agent antibactérien (peroxyde de benzoyle). Le gel à appliquer une fois par jour est actuellement disponible via la plupart des assurances privées, avec des projets d'élargir son accès par d'autres régimes publics de médicaments à travers le Canada.
Bausch Health Canada (NYSE:BHC) gab bekannt, dass seine Akne-Behandlung CABTREO nun über öffentliche Arzneimittelprogramme in Ontario und Nova Scotia sowie zwei Bundesprogramme – die Non-Insured Health Benefits (NIHB) für indigene Bevölkerungsgruppen und den Correctional Service of Canada (CSC) – verfügbar ist.
CABTREO ist eine erstmalige topische Verschreibungstherapie mit dreifacher Wirkstoffkombination gegen Akne vulgaris, die von Health Canada für Patienten ab 12 Jahren zugelassen wurde. Die Behandlung kombiniert drei Wirkmechanismen: ein Antibiotikum (Clindamycinphosphat), ein Retinoid (Adapalen) und ein antibakterielles Mittel (Benzoylperoxid). Das einmal täglich anzuwendende Gel ist derzeit über die meisten privaten Versicherungen erhältlich, mit Plänen, den Zugang über weitere öffentliche Arzneimittelprogramme in ganz Kanada zu erweitern.
- First and only triple-combination topical acne treatment approved by Health Canada
- Expanded market access through multiple public drug plans and federal programs
- Already available through most private insurance plans with plans for further expansion
- Limited current availability - not yet accessible through all Canadian public drug plans
This press release updates the headline of the previously posted release
LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) gel
CABTREO is a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older. CABTREO is the first and only triple-combination topical treatment for acne approved by Health Canada with three mechanisms of action - an antibiotic, a retinoid and an antibacterial agent - to provide a safe and effective treatment.1
"It is very encouraging for people with acne vulgaris who use the Ontario, Nova Scotia and federal drug plans to now have access to CABTREO along with those on most private drug insurance plans," said Amy Cairns, General Manager, Bausch Health, Canada Inc. "We look forward to completing listing arrangements in the near future with other public drug plans across Canada."
"We are pleased that public drug plans are ensuring Canadians with acne have access to new treatments, recognizing the importance of making different options available," said Kathy Giangaspero, Executive Director of the Acne and Rosacea Society of Canada. "Acne can significantly impact a person's mental and physical health, so this is a big win for the patient community."
CABTREO, a prescription product, is a topical gel that is administered once daily to affected areas of the skin. Its active ingredients are the antibiotic clindamycin phosphate, the topical retinoid adapalene and the oxidizing agent benzoyl peroxide with a broad-spectrum bactericidal activity.1
About Acne Vulgaris
Acne vulgaris ("vulgaris" means "common") is the most common skin problem seen by doctors in Canada. It occurs when the pores of the skin become plugged with oil and skin cells, often causing whiteheads, blackheads, pimples or cysts to appear on the face, forehead, chest, upper back and shoulders. Acne affects about 5.6 million Canadians, or nearly 20 per cent of the population, including about 90 per cent of adolescents. About 25 per cent of teens will still have acne at age 25. Acne causes emotional distress and can cause permanent scarring.2 It can also cause skin pigmentation changes.3
CABTREO Clinical Data and Safety Information
CABTREO was studied in two phase 3 multicentre, randomized, placebo controlled clinical trials in 363 patients with facial acne vulgaris. Both studies met all co-primary efficacy endpoints, including absolute change from baseline in inflammatory lesion count, absolute change from baseline in non-inflammatory lesion count, and percentage of patients achieving pre-defined treatment success. Combined efficacy results for both trials for CABTREO achieved approximately
The most frequent adverse reactions that may occur with CABTREO are mild to moderate application site reactions, such as skin irritation characterized by scaling, dryness, erythema, and burning/stinging. CABTREO should not be used by those who are hypersensitive to any of the ingredients in it (clindamycin phosphate, adapalene, benzoyl peroxide or to any ingredient in the formulation), patients with a history of regional enteritis (Crohn's disease), ulcerative colitis or antibiotic-associated colitis or by pregnant women and women planning a pregnancy. CABTREO may bleach hair and coloured fabric so caution should be used when applying it near the hairline.1
Health Canada has not authorized CABTREO for pediatric use under the age of 12 years. CABTREO is for topical use only and is not for oral, ophthalmic or intravaginal use.1
About Dermatology at Bausch Health, Canada Inc.
Bausch Health, Canada Inc. has one of the largest prescription dermatology businesses in Canada dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The Bausch Health, Canada Inc. dermatology portfolio includes several leading acne, psoriasis, anti-fungal and corticosteroid-responsive dermatoses products.
CABTREO is the fourth new dermatology treatment from Bausch Health, Canada Inc. approved by Health Canada and made available to Canadians over the past four years, adding to the company's leading portfolio in this important treatment area. The other approvals were for ARAZLOTM (tazarotene lotion,
All four treatments - CABTREO, ARAZLO, BRYHALI and DUOBRII - are manufactured at Bausch Health's Laval, Quebec, facility for Canada and the United States.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.
The Bausch Health Canadian prescription treatment portfolio is focused on dermatology, gastrointestinal and cardio-metabolic conditions. Bausch Health also has two manufacturing facilities for prescription pharmaceuticals in Canada: in Laval, Quebec, and Steinbach, Manitoba. More information can be found at the Company's website at www.bauschhealth.ca.
Forward-looking Statements
This news release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
REFERENCES
1 Bausch Health, Canada Inc., CABTREO Product Monograph, https://pdf.hres.ca/dpd_pm/00076715.PDF.
2 Canadian Dermatology Association, Acne, Quick Facts, https://dermatology.ca/public-patients/skin/acne/#:~:text=Acne%20affects%
3 "What to Know about Hyperpigmentation Acne." Medical News Today, Jessica Caporuscio, April 28, 2021, https://www.medicalnewstoday.com/articles/hyperpigmentation-acne, accessed Aug. 20, 2024.
4 Bausch Health, Canada Inc., Canadian Product List, https://bauschhealth.ca/products/canadian-product-list/.
Investor Contact: | Media Contact: |
SOURCE: Bausch Health Companies Inc.
View the original press release on ACCESS Newswire
FAQ
What is Bausch Health's CABTREO and what is it used for?
Which public drug plans now cover Bausch Health's CABTREO treatment?
How is BHC's CABTREO different from other acne treatments?
How is CABTREO administered to patients?
Will BHC's CABTREO be available through other Canadian public drug plans?
